Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aristolochic acid** is a mixture of structurally related nitrophenanthrene carboxylic acids, primarily aristolochic acid I (AA-I) and aristolochic acid II (AA-II), naturally occurring in Aristolochiaceae plants and some Asarum species. It is a potent nephrotoxin and carcinogen, historically used in traditional herbal medicine for conditions like arthritis, amenorrhea, weight loss, and as an immune booster. Aristolochic acid is absorbed orally and distributed systemically; its metabolism leads to DNA adduct formation, particularly in renal tissue, contributing to mutagenesis and a unique TP53 mutational signature. The primary health risks are aristolochic acid nephropathy (rapidly progressive interstitial renal fibrosis) and urothelial carcinomas, especially of the upper urinary tract and bladder. There is no approved therapeutic application, and its use is banned or heavily restricted in many countries due to safety concerns[1][2][3][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aristolochic acid.